Date: Sunday, April 30, 2017
Session Name: Poster Session B: Living Donors and Partial Grafts
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
In patients with living donor liver transplantation (LDLT), late-onset complications sometimes develop and most of them are related to immunosuppressive drugs.
Patients and Methods:
In151 patients (25 children, 126 adults) with LDLT (2002.2-2016.12), we retrospectively reviewed the medical records of 97 adult LDLT patients, who had been followed-up at our hospital more than one year after LDLT. The average age of them was 52.9 years old (20-70) and the median observational period was 6.0 years (1.7-14.4). An annual checkup and screening examinations were performed as follows: abdominal computed tomography, upper gastrointestinal endoscopy, and fecal occult blood test every 1 to 2 years. Complete blood count, liver function tests, and tumor markers were checked every 1 to 3 months after LDLT.
During the follow-up period, late onset complications developed 19.1% (17/89) of chronic kidney disease, 13.4% (11/82) of new onset diabetes mellitus, 11.3% (11/97) of born fracture, 11.3% (11/97) of de novo malignancy, and 8.3% (8/97) of cerebral vascular disease, including overlapping. Forty two patients (43.3%) had never experienced late-onset complications. The diagnoses of de novo malignancies were posttransplantation lymphoproliferative disorder (PTLD) (n=4) (2 in brain and 2 in abdominal lymph nodes), lung cancer (n=1), pancreatic cancer (n=1) gastric cancer (n=1), laryngeal cancer (n=1), lower gingival cancer (n=1), bladder cancer (n=1), and melanoma (n=1). The average age at cancer diagnosis was 61 years old (36-70) and the interval from LDLT to cancer diagnosis was 8.3 years (3.9-12.2). Four patients (36.6%) died of cancer and all of them were diagnosed as cancer within 10 years after LDLT.
Late-onset complication related to immunosuppressive drug developed in more than half of adult LDLT recipients. Long-term close follow-up should be performed by taking any kinds of late onset complications into consideration.
CITATION INFORMATION: Mizuno S, Iizawa Y, Kato H, Murata Y, Tanemura A, Kuriyama N, Kishiwada M, Usui M, Sakurai H, Isaji S. Incidence of Late-Onset Complications Related to Immunosuppressive Drugs Following Adult to Adult Living Donor Liver Transplantation, Especially Focusing on De Novo Malignancy. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Mizuno S, Iizawa Y, Kato H, Murata Y, Tanemura A, Kuriyama N, Kishiwada M, Usui M, Sakurai H, Isaji S. Incidence of Late-Onset Complications Related to Immunosuppressive Drugs Following Adult to Adult Living Donor Liver Transplantation, Especially Focusing on De Novo Malignancy. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-of-late-onset-complications-related-to-immunosuppressive-drugs-following-adult-to-adult-living-donor-liver-transplantation-especially-focusing-on-de-novo-malignancy/. Accessed October 29, 2020.
« Back to 2017 American Transplant Congress